Thymoma & thymic carcinoma

The thymus lies in the front of the chest behind the breastbone. Thymoma arises from thymic epithelial cells and is classified into types A, AB, B1, B2 and B3, with additional uncommon variants. These labels describe microscopic appearance, not how far the tumor has spread. A lower-risk appearance does not make an invasive thymoma harmless.

Thymic carcinoma usually behaves more aggressively and may spread to lymph nodes or distant organs. Expert pathology should distinguish it from metastatic cancer, lymphoma and thymic neuroendocrine tumors. Neuroendocrine tumors follow their own classification and treatment considerations.

Contrast-enhanced chest CT evaluates the mass, surrounding vessels, lung and pleura. MRI can clarify a cystic lesion or uncertain invasion. The team may check blood markers and other tests when lymphoma or a germ-cell tumor is possible. A PET scan is selective rather than a substitute for diagnosis.

If imaging strongly suggests thymoma and complete resection is feasible, a specialist team may recommend surgery without a preoperative biopsy. If the diagnosis is uncertain or induction/systemic therapy is planned, tissue confirmation is important. Biopsy route and specimen size should be planned to provide useful pathology while avoiding unnecessary tumor or pleural disruption.

Drooping eyelids, double vision, chewing fatigue, swallowing difficulty or fluctuating weakness may signal myasthenia gravis. Assessment may include acetylcholine-receptor antibodies and neurological review. Known myasthenia should be stabilized before major surgery, with an anesthesia and respiratory plan; removing the tumor does not guarantee that myasthenia disappears.

Thymoma can also accompany pure red-cell aplasia or immunodeficiency such as Good syndrome. Unexplained anemia or repeated infections deserve targeted investigation. New breathing or swallowing weakness needs urgent assessment, especially around surgery or immunotherapy.

The ninth-edition TNM system separates T1 tumors by a 5 cm size threshold and places direct lung or phrenic-nerve invasion in T2. Nodes, pleural/pericardial deposits and distant metastases also affect stage. An older report may use an earlier TNM edition or Masaoka–Koga; ask which system was used before comparing stage numbers.

Resectability is a separate multidisciplinary judgment. The key question is whether the tumor can be removed completely with acceptable effects on major vessels, heart, lungs and nerves. R0 means no tumor at the microscopic margin; R1 means microscopic residual disease and R2 visible residual disease. These findings influence postoperative treatment.

Complete surgery is the foundation for resectable disease. Surgical extent and an open or minimally invasive approach depend on anatomy, invasion and safe oncologic clearance. Lymph-node assessment is particularly important in thymic carcinoma. A smaller incision should not compromise complete removal.

Postoperative radiation is not automatic after every thymoma operation. Completely resected early thymoma is often observed; stage, aggressive histology, involved margins and other invasion features can change the recommendation. Thymic carcinoma more often warrants discussion of postoperative radiation. Review the operative and pathology reports together, including heart and lung exposure in the radiation plan.

For a tumor not initially removable but potentially convertible to surgery, induction chemotherapy followed by reassessment can be considered. Definitive radiation or chemoradiation may be appropriate when surgery is not feasible. Selected pleural recurrence or limited spread can sometimes be treated locally, but extensive disease usually needs a systemic strategy.

Regimens differ by histology. Cisplatin, doxorubicin and cyclophosphamide is an established thymoma combination, while carboplatin–paclitaxel is commonly used for thymic carcinoma. Prior treatment, heart function, neuropathy and overall fitness matter. The plan should state whether the aim is conversion to local treatment, prolonged control or symptom relief.

For previously treated thymic carcinoma, lenvatinib and sunitinib have prospective phase II evidence. Japan has a lenvatinib indication for unresectable thymic carcinoma; authorization and access elsewhere must be checked locally. These data do not establish the same benefit for every thymoma subtype or a universally best sequence.

Blood pressure, cardiac function, proteinuria, bleeding risk and tolerance need active management with antiangiogenic drugs. Everolimus has shown disease-control activity, but its study reported fatal pneumonitis. Additional chemotherapy or a trial may be preferable depending on prior response and the patient's risks; an oral medicine is not necessarily a gentler choice.

Pembrolizumab has demonstrated activity in previously treated thymic carcinoma, but studies also reported serious immune toxicity, including myocarditis. Thymoma has a particularly concerning risk of myasthenia, muscle and heart inflammation. High PD-L1 alone does not make checkpoint treatment safe; pre-existing autoimmune disease and specialist monitoring are central to selection.

The 2025 PECATI study evaluated lenvatinib plus pembrolizumab in 43 previously treated patients with thymic carcinoma or B3 thymoma without autoimmune disorders. It was a single-arm phase II study, with promising disease control but serious adverse events. It does not show superiority to lenvatinib alone, establish a routine first-line regimen or justify extending treatment to all thymomas.

Thymoma may recur many years after initial treatment, so follow-up extends well beyond the first few years. Imaging frequency depends on histology, stage, margins and earlier treatment. New lesions should be reviewed for local salvage options before assuming that only lifelong systemic treatment is possible.

Clinical trials are especially important for these rare cancers. Eligibility may depend on exact histology, prior platinum, autoimmune history and organ function. Broad tumor profiling can be discussed in advanced disease to look for rare actionable findings or trial matches, but a detected alteration does not guarantee an effective approved treatment.

Bring pathology slides or blocks, imaging files, staging reports, the operation note with margin details, previous radiation plans and a dated treatment history. Include neurological assessments, antibody results, autoimmune medicines and any episodes of severe infection or transfusion-dependent anemia.

Ask the team to define the diagnosis, resectability, realistic treatment goal and safety plan. For a cross-border treatment option, confirm the applicable indication, trial site and actual intake arrangements before travel; a published study does not itself establish access through Chirona.